Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Immuneering (IMRX) Cost of Revenue (2020 - 2022)

Immuneering's Cost of Revenue history spans 3 years, with the latest figure at $19343.0 for Q3 2022.

  • On a quarterly basis, Cost of Revenue fell 91.17% to $19343.0 in Q3 2022 year-over-year; TTM through Jun 2023 was $19343.0, a 96.57% decrease, with the full-year FY2022 number at $158122.0, down 86.29% from a year prior.
  • Cost of Revenue came in at $19343.0 for Q3 2022, down from $47933.0 in the prior quarter.
  • The five-year high for Cost of Revenue was $473233.0 in Q4 2020, with the low at $19343.0 in Q3 2022.
  • Historically, Cost of Revenue has averaged $233649.2 across 3 years, with a median of $228075.0 in 2020.
  • Biggest five-year swings in Cost of Revenue: surged 34.4% in 2021 and later crashed 91.17% in 2022.
  • Year by year, Cost of Revenue stood at $473233.0 in 2020, then crashed by 56.42% to $206221.0 in 2021, then tumbled by 90.62% to $19343.0 in 2022.
  • Business Quant data shows Cost of Revenue for IMRX at $19343.0 in Q3 2022, $47933.0 in Q2 2022, and $90846.0 in Q1 2022.